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Introduction
People who inject drugs (PWID) are a key population at risk
of hepatitis C virus (HCV) and HIV infections. Globally, 63% of
PWID are HCV infected [1,2] and 19% are HIV infected [2],
leading to an estimated 10 million and 3 million HCV- and
HIV-infected PWID, respectively [13]. The Middle East and
North Africa (MENA), a region comprising 23 countries from
Morocco in the West to Pakistan in the East, is at the centre
of major drug production and trade, creating a context of
vulnerability to injecting drug use [4]. PWID in MENA are a
large, mostly young and stigmatized population experiencing
a substantial HCV and HIV burden, with potential for even
further HIV epidemic growth. Yet, they lack access to com-
prehensive and confidential HCV and HIV testing, prevention
and treatment services [5].
A large population at risk
MENA is home to an estimated 626,000 current PWID
(range: 335,0001,635,000) [6], with Iran, Pakistan and Egypt
bearing the largest numbers [6]. The population proportion
of PWID, at 0.24 per 100 adults, is comparable to global
figures [2], but highest in the Eastern part of the region, such
as in Iran at 0.43 per 100 adults [6].
A substantial HCV infection burden
Overall, about half of PWID in MENA are HCV infected
(median: 44%; interquartile range (IQR): 3164%), and
prevalence as high as 90% has been reported among some
PWID populations [6] (Figure 1). In addition to the estimated
300,000 HCV-infected current PWID [6], there could be as
many as 2 million HCV-infected people who acquired the
infection through past drug injection, but are no longer
injecting. In the United States, for example, the number of
HCV-infected previous PWID is more than seven times the
number of HCV-infected current PWID [7].
The high HCV prevalence and the injecting risk behaviour
environment suggest substantial ongoing HCV transmission
[6]. This is affirmed by measured and estimated HCV incidence
among PWID. In one study in Afghanistan, for example, an
HCV incidence rate of 67 per 100 person-years (pyr) has been
reported [8]. Preliminary mathematical modelling results
suggest that PWID are a major driver of HCV incidence in
MENA (Mumtaz et al., under preparation).
Emerging and growing HIV epidemics
Recent evidence has documented HIV epidemics among PWID
in one-third of MENA countries [6]. The scale of the epidemic
among PWID could be underestimated as the epidemic status
remains unknown in half of MENA countries [6]. In some
settings, HIV prevalence has reached unprecedented levels,
such as in Tripoli, Libya at 87.2% [9]. The common pattern,
however, remains that of emerging concentrated epidem-
ics such as in Afghanistan and Egypt [6]. Most epidemics
occurred only in the last decade and HIV prevalence hovers
around 1015% [6].
There is also evidence for substantial HIV incidence among
PWID. HIV incidence rates of 1.7 [10], 2.2 [8] and 17.2 [11]
per 100 pyr have been reported in Pakistan, Afghanistan and
Iran, respectively. Modelling work has estimated high in-
cidence in Iran with the majority of infections being due
to drug injection [12]. Case notifications also suggest a
dominant contribution of PWID to HIV incidence in Afghanistan
and Libya [6].
The early phase of the HIV epidemics and the prevalence
of risky injecting and sexual practices suggest potential for
further HIV epidemic growth among PWID [6]. Recent pre-
dictions suggest moderate to high HIV epidemic potential
among PWID in countries such as Afghanistan, Egypt, Lebanon,
Morocco, Palestine, Saudi Arabia, Syria and Tunisia [13].
Moving forward
There is an urgent need to prioritize PWID for interventions
and to scale up harm reduction services in MENA. In 2014,
needle/syringe exchange programmes (NSPs) were imple-
mented in ten MENA countries, and opioid substitution
therapy (OST) in six [14]. These do not include Libya and
Saudi Arabia, countries with high HCV prevalence among
PWID (Figure 1). Among the other countries with substantial
HCV infection burden, Morocco is the only one with opera-
tional NSP and OST programmes, while in Pakistan and Egypt
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only NSPs are provided. Iran remains the leader in harm
reduction with an NSP coverage of 5577% among PWID in
2014, and provision of OST through 4200 centres [14]. Limited
funding, low and heterogeneous coverage of services, socio-
cultural stigma and fear of arrest persist as major barriers for
access and provision of harm reduction services [14]. MENA
countries could benefit from Iran’s experience in implement-
ing harm reduction within the regional social-cultural context.
With most PWID starting injecting at a young age, harm re-
duction should be adapted for young people and linked to
other sectors such as education and employment [15].
Alongside prevention interventions, the recent availability
of highly effective direct-acting antivirals to treat HCV offers
hope for HCV-infected PWID. The prohibitively expensive cost
of the drugs remains a major challenge for scale-up. Ensuring
affordable access to treatment will only be possible with
generic competition or with substantial price reductions on
existing or upcoming drugs such as the 99% price discount
negotiated by Egypt [16] and a similar discount negotiated
recently by Pakistan. Generics are planned to be manufac-
tured within the region, such as in Egypt and Morocco.
Generics are being produced in India for as little as $750 for a
full treatment course, and production costs may go down to
$100 within a few years [17]. As the first Global Health Sector
Strategy on Viral Hepatitis is being drafted, concerted efforts
are needed for the development of National Strategic Plans
for Viral Hepatitis, and possibly Viral Hepatitis Programmes,
at country level in MENA, as is already materializing in a few
countries including Bahrain, Egypt, Lebanon and Iran. Such
programmes can furnish the logistical framework for sup-
porting HCV-related services among PWID through initiatives
including testing, treatment and optimally harm reduction, in
tandem with National AIDS Control Programme services.
As for HIV treatment, much remains to be accomplished in
a region that has one of the lowest antiretroviral therapy
(ART) coverages worldwide with a median coverage of 16%
(IQR: 617%) [18]. Limited HIV testing, the cost of ART to
burdened health care systems, and poor access are obstacles
for ART uptake and scale-up [19]. The median prevalence
of lifetime HIV testing among PWID is 33% (IQR: 1656%),
and is very low in many countries with concentrated HIV
epidemics such as in Afghanistan, Pakistan and Egypt [6].
While Voluntary Counselling and Testing (VCT) has been
initiated in most countries, uptake of services has been over-
all weak, partially because of weak non-governmental organi-
zations (NGO) involvement, limited engagement of PWID,
and social stigma [5]. Morocco is one exception where the
strong civil society has facilitated broad and sizable access
to VCT services for different populations [5]. Provision and
access to HCV testing is even more limited because of the
poor commitment to HCV treatment. Managing the structur-
al barriers of social stigma, poverty, homelessness, crimina-
lization and incarceration will facilitate both HIV and HCV
testing, treatment and prevention scale-up for PWID in
MENA [20].
Conclusions
There is a large marginalized population of over half a million
PWID in MENA, half of whom are already HCV infected. There
is also a larger population of HCV-infected previous injectors
who are progressing through the natural course of disease
without knowing the status of their infection or the oppor-
tunity of treatment. PWID in MENA are also enduring rising
HIV epidemics, some of which have already reached high
HIV prevalence. Advantage should be taken from the global
momentum for tackling viral hepatitis, and courageous deci-
sions are needed at the national level to develop or expand
programmes that can tackle HCV and HIV public health burden
among PWID. Scale-up of treatment and harm reduction
services should be a main pillar of such programmes, along-
side innovative strategies to overcome the challenges im-
posed by social stigma and criminalization.
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